Francis Medical Showcases Minimally Invasive Prostate Ablation Technology

A LinkedIn post from Francis Medical highlights comments from Dr. Christopher Dixon suggesting that the company’s Vanquish Water Vapor Ablation System may help reduce life-altering side effects associated with conventional, more aggressive prostate treatments. The post describes Vanquish as using sterile water vapor to ablate prostate tissue via a targeted transurethral procedure and notes that the system is FDA cleared and available by prescription only.

For investors, the emphasis on minimally invasive prostate therapy positions Francis Medical in a large and growing urology market where quality-of-life outcomes are becoming a stronger adoption driver. If clinical and real-world data continue to support reduced side effects relative to standard treatments, the technology could support higher physician uptake, pricing power, and potential reimbursement advantages, strengthening the company’s competitive profile in prostate care devices.